



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

June 17, 2020

Nancy Simonian, M.D.  
President and Chief Executive Officer  
Syros Pharmaceuticals, Inc.  
35 CambridgePark Drive, 4th Floor  
Cambridge, Massachusetts 02140

**Re: Syros Pharmaceuticals, Inc.**  
**Registration Statement on Form S-3**  
**Filed June 12, 2020**  
**File No. 333-239141**

Dear Dr. Simonian:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Cynthia Mazareas